Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model.

Waterhouse, Dawn N; Gelmon, Karen A; Masin, Dana; Bally, Marcel B

Waterhouse, Dawn N; Gelmon, Karen A; Masin, Dana; Bally, Marcel B.

Affiliation

Waterhouse DN; British Columbia Cancer Research Centre, Department of Advanced Therapeutics, Vancouver, Canada. dwater@bccancer.bc.ca

J Exp Ther Oncol ; 3(5): 261-71, 2003.

Article in En | MEDLINE | ID: mdl-14696623

Subject(s)

Antibiotics, Antineoplastic/therapeutic use; Doxorubicin/therapeutic use; Mammary Neoplasms, Experimental/drug therapy; Oligonucleotides, Antisense/therapeutic use; Receptor, ErbB-2/genetics; Animals; Area Under Curve; DNA-Binding Proteins/genetics; DNA-Binding Proteins/physiology; Disease Models, Animal; Down-Regulation; Drug Therapy, Combination; Female; Flow Cytometry; Humans; Liposomes; Mammary Neoplasms, Experimental/metabolism; Mammary Neoplasms, Experimental/pathology; Mice; Mice, SCID; Nuclear Proteins; Receptor, ErbB-2/metabolism; Tumor Cells, Cultured

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Doxorubicin / Oligonucleotides, Antisense / Receptor, ErbB-2 / Mammary Neoplasms, Experimental / Antibiotics, Antineoplastic Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: J Exp Ther Oncol Journal subject: NEOPLASIAS / TERAPIA POR MEDICAMENTOS Year: 2003 Document type: Article Affiliation country: Canada Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links